Enlonstobart

恩朗苏拜单抗

Report date: 2025/10/20 14:43:23

Base Information

Drug NameEnlonstobart
Drug Alias Name恩朗苏拜单抗注射液重组抗 PD- 1 全人源单克隆抗体注射液恩舒幸SG-001SYSA1802
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsSolid tumoursUterine Cervical NeoplasmsEndometrial Neoplasms +[20] 
Global Approved IndicationsUterine Cervical Neoplasms
Approved Indications in ChinaUterine Cervical Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2024/06/25
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesHangzhou Shangjian Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCspc Zhongqi Pharmaceutical Technology (Tianjin) Co LtdJushi Biopharmaceutical Co LtdCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd +[6] 
Inactive CompaniesCspc Ouyi Pharmaceutical Co Ltd
Active IndicationsSolid tumoursUterine Cervical NeoplasmsEndometrial Neoplasms +[14] 
Inactive IndicationsGallbladder NeoplasmsBiliary Tract NeoplasmsCholangiocarcinoma +[6] 

Other Information

ATC CodeN/A
Related LinksN/A